Indian court rejects AstraZeneca’s injunction request
24-11-2020
Seagen targets Daiichi in cancer drug suit
22-10-2020
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30-07-2020
Pavel Kapysh / Shutterstock.com
Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, Daiichi Sankyo, Seagen, breast cancer, patent infringement, biopharmaceutical
